Stock AMGN34 AMGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Amgen Inc. Sao Paulo

Equities

AMGN34

BRAMGNBDR004

Market Closed - Sao Paulo
Other stock markets
 12:48:13 20/06/2024 am IST 		5-day change 1st Jan Change
58.56 BRL +18.33% Intraday chart for Amgen Inc. +0.43% +17.24%
14/06 Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto DJ
14/06 Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company returns high margins, thereby supporting business profitability.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • One of the major weak points of the company is its financial situation.
  • With an expected P/E ratio at 38.58 and 24.8 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
AMGEN INC. Stock Amgen Inc.
+17.24% 164B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+52.93% 803B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.98% 631B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.08% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.40% 324B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.58% 303B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.42% 243B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.17% 228B
A+
NOVARTIS AG Stock Novartis AG
+10.66% 217B
B-
PFIZER, INC. Stock Pfizer, Inc.
-4.79% 155B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. AMGN34 Stock
  5. Ratings Amgen Inc.